AMASS Brands Issued Guidance Through 2027 That Its Own Release Says Does Not Assume the Capital It Still Needs to Raise

by Adam Kowalczyk · August 18, 2026

Filings & Deals Reporter, The MicroCap Herald

AMASS Brands Inc. (Nasdaq: AMSS), a Santa Maria, California beverage company that reached the exchange by direct listing in May, reported second-quarter results before Monday's open and introduced revenue guidance running through fiscal 2027 — its first guidance as a public company. The same release discloses, in its forward-looking statements, substantial doubt about the company's ability to continue as a going concern. The release does not present the two as a contradiction. It states that the outlook "does not assume, and should not be read to reflect, the outcome of the Company's efforts to obtain the additional capital described above under 'Liquidity and going concern.'" The targets are what management expects to sell; the capital the company needs is a separate and unresolved question. The release carries no section under that heading, so the cross-reference points to material it does not contain.

The reported figures, all drawn from the August 17 release distributed through GlobeNewswire, are these. Second-quarter net revenue was $5.6 million, which the company described as up 2% from the prior-year quarter. Gross profit was $1.5 million, a 26.7% margin; adjusted gross profit was $1.6 million, or 29.3%. Adjusted EBITDA was negative $1.7 million. Cash and cash equivalents stood at $1.6 million at June 30, 2026; the release does not separately disclose restricted cash or total liquidity. The company said it had 11,605,081 common shares outstanding and 3,856,688 warrants outstanding. It also reported $0.4 million of net revenue in its non-alcoholic and functional segment, which it said was up 132% — a large percentage change on a base of well under half a million dollars.

The profitability headline in that list is a non-GAAP one. The release defines adjusted EBITDA and adjusted gross profit and states that a reconciliation of net loss, which it identifies as the most directly comparable GAAP measure, to adjusted EBITDA is included in the accompanying tables. The narrative highlights themselves do not carry a GAAP net loss, an operating cash flow figure, or a total debt balance. Adjusted EBITDA is not a measure of cash consumption, and readers should not treat the $1.7 million as the quarter's cash burn.

The outlook is the release's most unusual feature for a company at this size. AMASS said that "Based on current trends and management's operating plan, the Company expects a return to year-over-year growth in the second half of fiscal 2026, with second-half net revenues of at least $8.7 million, representing growth of at least approximately 10% over second-half fiscal 2025." The component targets are net revenues of at least $4.4 million in the third quarter and at least $4.3 million in the fourth, each characterized as growth of at least approximately 10%; at least $18.5 million for full-year 2026, growth of at least approximately 4%; and at least $22.2 million for full-year 2027, at least approximately 20%. The release frames all of it as the company "introducing financial guidance for the first time as a public company."

Two things follow from the company's own wording. The second-half targets are framed as year-over-year growth, not sequential growth: both quarterly figures sit below the $5.6 million the company just reported for the second quarter, and the release does not explain that step-down, though a portfolio weighted toward rosé wine would be expected to peak earlier in the year. Readers comparing the guidance with the quarter just reported are comparing against a different base than the company is. And the phrase "a return to" year-over-year growth is the company's own signal that the first half of 2026 did not grow against the first half of 2025, notwithstanding the 2% increase it reported for the second quarter alone.

The going-concern language appears in the release's forward-looking statements section rather than in a financial-statement note, and the release includes no note on management's going-concern assessment. The release lists among its risks "The substantial doubt regarding the Company's ability to continue as a going concern, and the effect that a failure to obtain additional capital would have on the Company's ability to execute the operating plan underlying its outlook." The same list names "the Company's need to raise additional capital and the terms on which that capital may be available."

The audit history behind that sentence is in the Form S-1 AMASS filed with the SEC on April 8, 2026, ahead of the listing. The prospectus states that the company's consolidated financial statements for the year ended December 31, 2025 "have been prepared on a going concern basis and include an explanatory paragraph from our independent auditors raising substantial doubt about our ability to continue as a going concern." The same document records 2025 net revenues of $17.8 million and a net loss of $17.2 million, against 2024 revenue of $21.7 million and a net loss of $15.2 million. On the prospectus's own labeling, the 2027 target of at least $22.2 million would be the first annual figure above the 2024 level.

The release also flags "the Company's past-due Mezzanine Secured Notes and its ability to extend, refinance or repay them." It gives no principal amount, no maturity and no counterparty. The April prospectus describes a $2.5 million secured promissory note issued in connection with the purchase of the AMASS trademark, held by Half Church Holdings Pte. Ltd. with a first-priority security interest in the trademark itself, that has been through payment defaults and multiple extensions, most recently to June 30, 2027. The prospectus does not use the label "Mezzanine Secured Notes" for that instrument, and this article does not equate the two. The amount now past due is not disclosed in the release.

The financing that will most likely determine the share count is a securities purchase agreement with Streeterville Capital, LLC. Per the April prospectus, the facility provides for up to $30 million of Series C convertible preferred stock — a maximum commitment, not an amount drawn; the documents reviewed for this article do not establish how much has actually been issued and remains outstanding. Shares are issued at a stated value of $1,086.96 per share against a purchase price of $1,000.00, an original issue discount, and carry a preferred return of 2% per quarter, which the prospectus states is 8% per annum, compounding daily and payable quarterly in cash or additional Series C shares at the company's election, increasing to 18% per annum upon certain events of default. The first closing on April 8, 2026 included 28,125 commitment shares — which the prospectus derives as $450,000 divided by a $16.00 reference price — and a warrant covering 3,500,000 shares.

The conversion mechanics matter more than the headline commitment. The prospectus says the Series C initially converts at a fixed price tied to the Nasdaq valuation price, but that after six months, a Trigger Event, or an event of default, the conversion price becomes the lesser of that fixed price or a market price defined as 90% of the lowest daily VWAP over the ten trading days prior to conversion, subject to a floor set at 40% of an applicable baseline price. Two readings of the prospectus differed on precisely which baseline the 40% floor attaches to, so this article does not specify it. Separate limits are a 9.99% beneficial ownership cap and an exchange cap arising under Nasdaq Rule 5635(d). Monday's release names the mechanism directly, listing among its risks "dilution associated with the Streeterville facility and with conversions at the alternate conversion price following the Series C Trigger Event."

There is a second dilution instrument with a shorter fuse. In an 8-K filed June 12, 2026, AMASS disclosed Amendment No. 2 to the Streeterville warrant, executed June 1, providing "a reduced exercise price of $3.0 per share for any exercise occurring during the ninety (90) day period commencing on the effective date of the Warrant Amendment," after which "the exercise price will be $16.00 per share." The company may end the reduced-price period "at any time upon two (2) trading days' prior written notice." The filing does not state the effective date separately from the June 1 execution date, and no other filing reviewed supplies it, so the expiry of the reduced-price window cannot be dated from the public record and this article does not estimate one. All other warrant terms were left unchanged. The prospectus also gives Streeterville consent rights over the moves a micro-cap in this position would normally reach for: incurring debt other than trade payables, issuing equity or convertible instruments, disposing of assets above $500,000, granting security interests, effecting a reverse stock split, and creating additional series of preferred stock, subject to specified exempt issuances including bank debt, employee equity plans, up to $15 million of merger-and-acquisition-related issuances, and any financing that fully redeems the Series C. Any recapitalization, in other words, runs through the same counterparty whose paper sits at the front of the dilution question.

On listing status, the release's risk list refers to "the Company's ability to regain and maintain compliance with the Nasdaq continued-listing requirements." The word "regain" implies something is not currently in compliance, but the release does not identify a rule, a notice date or a deadline, and no filing reviewed for this article disclosed a deficiency notice. Readers should treat the compliance position as undisclosed rather than as either clean or deficient. The company's own documents are also inconsistent about which Nasdaq tier it trades on: the May 20 listing release says the stock would begin trading on the Nasdaq Capital Market, while Monday's release and the cover pages of the June 8-Ks say Nasdaq Global Market. Because two renderings genuinely disagree, this article says only "Nasdaq" and does not pick between them.

Against $1.6 million of quarter-end cash and cash equivalents, the company has been committing money outward. A June 24 release and an 8-K filed June 16, 2026 disclose that AMASS "invested $1,435,000" in a simple agreement for future equity in AfterDream, Inc., a hemp-derived THC beverage brand, at a post-money valuation cap of $7,500,000; on June 17 the purchase amount was increased by $100,000 to $1,535,000. The instrument converts only on an equity financing, a liquidity event or a dissolution event. Monday's release separately describes a planned acquisition of a majority stake in HpO Sparkling Protein Water, characterized as approximately 50% on a fully diluted basis. The AfterDream commitment is close in size to the entire quarter-end cash balance, though the two are measured at different dates and cannot be netted against each other; the release does not quantify either commitment against the balance sheet.

The market-share claims in the release are the company's characterization of third-party data and cannot be verified from the release itself. AMASS says Good Twin "claimed the #1 position in the U.S. organic non-alcoholic wine category by dollar share" and that Pizzolato "claimed the #1 position in the U.S. organic sparkling wine category by dollar share," and describes "Summer Water Rosé, confirmed by Nielsen as the #1 best-selling domestic rosé in the $15–$20 price tier." Each is a rank within a narrowly defined category rather than a statement about the size of the business, and the underlying Nielsen data is not public.

On news flow, the releases AMASS distributed through GlobeNewswire in the months around the listing were weighted toward launches, distribution wins and category-rank claims: a May 20 direct-listing announcement, a May 27 release headlining Good Twin as the #1 organic non-alcoholic wine brand in the U.S., a May 28 electrolyte-mixer launch, a June 5 first U.S. distribution partner for those mixers, the June 24 AfterDream investment, a June 29 announcement of the HpO stake, and Monday's results. A search of the wire surfaced no further releases between the end of June and the August 17 results, and this article does not assert a complete count. What is clear from the pattern is where the hard disclosures went: the Streeterville facility, the past-due notes and the going-concern doubt reached investors through SEC filings and through a risk paragraph at the bottom of an earnings release, not through headlines of their own.

The April prospectus also discloses a supplier concentration that has already produced losses. A multi-year production agreement with Full Glass Wine Co. carries fixed-price and minimum-purchase obligations that the prospectus says required sales below cost of production, producing a $0.8 million loss on the sale of finished goods under those contracts and a $2.9 million liability on firm purchase commitments in 2024, with the related liability at $3.0 million as of December 31, 2025. The prospectus says Full Glass is currently in default under that agreement and that a settlement is being negotiated. The prospectus also discloses a regulatory event the earnings release does not mention: the company ceased its Pennsylvania operations in 2024 after notice from the Pennsylvania Liquor Control Board that it was no longer permitted to operate in the Commonwealth. On litigation, the prospectus describes a March 2025 settlement and lease termination with VV1515 LLC over a former Bethel Township, Pennsylvania facility, under which the landlord retained a $300,000 security deposit and the company agreed to pay a further $75,000 in installments, resolving proceedings in the U.S. District Court for the Eastern District of Pennsylvania. No pending securities or intellectual-property litigation against the company surfaced in searches of public sources or in the prospectus's legal proceedings disclosure.

The float is small and the registered supply is not. The May 20 direct listing raised no capital — the company's own release states that "The direct listing did not involve the issuance of new common stock by the Company" — and 11.6 million shares were outstanding as of June 30. The April prospectus registered the resale of up to 12,432,021 shares by existing holders. Those two counts are taken at different dates and measure different things, and should not be netted against one another; the point is only that the quantity of stock registered for resale by existing holders exceeds the quantity outstanding, into a thinly traded stock.

The items that would settle most of the open questions are not in Monday's release. The quarterly report on Form 10-Q will carry the GAAP bottom line, the operating cash flow, the principal balance and maturity of the past-due Mezzanine Secured Notes, and the note describing management's going-concern assessment. The reconciliation the release points to will show what sits between net loss and the negative $1.7 million of adjusted EBITDA. And the date on which the Series C alternate conversion price becomes available, together with the amount of the facility actually drawn, will determine how many shares the guidance through 2027 is eventually measured across.